Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View Full Press Release Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027